Previous 10 | Next 10 |
JERSEY CITY, N.J. , Oct. 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data from a post-hoc analysis of the Phase 2b DOVE study ...
JERSEY CITY, N.J. , Oct. 24, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced an amendment to the protocol for the ongoing FURI study investigating ...
JERSEY CITY, N.J. , Oct. 10, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, has received notification from the State of New Jersey of its available unused net opera...
JERSEY CITY, N.J. , Oct. 2, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data, which further demonstrates the potential of ibrexafung...
WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical ...
Gainers: SPI Energy Co. (NASDAQ: SPI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +22% . DAVIDsTEA (NASDAQ: DTEA ) +17% . Dynagas LNG Partners LP (NYSE: DLNG ) +12% . Edesa Biotech (NASDAQ: EDSA ) +12% . SCYNEXIS (NASDAQ: SCYX ) +11% . Eyenovia (NASDAQ: EYEN ) +10% . elect...
Thinly traded nano cap SCYNEXIS ( SCYX +11% ) is up on more than a 4x surge in volume in reaction to the completion of the last visit for the last patient in its Phase 3 clinical trial, VANISH 303, evaluating ibrexafungerp (formerly SCY-078) for the treatment of fungal infections, ...
JERSEY CITY, N.J. , Sept. 18, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced completion of the last-patient/last-visit in its Phase 3 VANISH...
JERSEY CITY, N.J. , Sept. 4, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present in the following investor conferences: The...
Immunomedics (NASDAQ: IMMU ) initiated with Overweight rating and $28 price target at Cantor Fitzgerald. More news on: Immunomedics, Inc., SCYNEXIS, Inc., AbbVie Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...